Browsing Tag

Executive Insights

74 posts

Market View: Parenteral Drugs
By

By
Parenteral drugs are an important part of the pharmaceutical market due to the increase in biologics and complex active pharmaceutical ingredients (APIs) in development. DCAT Value Chain Insights examines key…

Procurement and Supply-Chain Leaders: Top Five Issues
By

By
What are the key issues facing procurement and supply-chain leaders? From digital transformations to talent development to risk mitigation, DCAT Value Chain Insights provides perspective from thought leaders. Providing perspective…

Emerging Pharma: Roivant Sciences on the Rise
By

By
With a $3-billion strategic alliance with Sumitomo Dainippon Pharma in the offing, Vivek Ramaswamy, CEO and founder of Roivant Sciences, is looking to take its “hub and spoke” business model…

Sustainable Sourcing and Climate Change: How are Measures Changing?
By

By
Sustainable sourcing practices, aligned with companies’ environmental, health and safety (EHS) goals and corporate social responsibility initiatives, are taking on greater prominence as part of a broader global discussion on…

Top 10: Investments & Moves in Bio/Pharma Manufacturing
By

By
What are the key developments in bio/pharmaceutical manufacturing? From large-scale biomanufacturing projects, to mergers and acquisitions involving cell and gene therapy production, to continuous manufacturing, DCAT Value Chain Insights looks…

 FDA and EMA Broaden Review of Impurities in API Manufacturing
By

By
The FDA and the European Medicines Agency (EMA) are expanding their scope of investigation to evaluate other active pharmaceutical ingredients (APIs) that contain nitrosamine impurities, an issue that first surfaced…

The Marriage of Mylan and Pfizer’s Upjohn
By

By
Earlier this month, Mylan and Pfizer agreed to combine Mylan with Upjohn, Pfizer’s off-patent branded and generic established medicines business. The deal is expected to close in mid-2020 and will…

Generic-Drug Approvals: FDA OK in First Review Hard to Get
By

By
A recent analysis by the US Government Accountability Office shows that only 12% of the 2,030 generic drug applications reviewed by the FDA from fiscal years 2015 through 2017 were…

Inside the Trenches: End-To-End CDMOs/CMOs
By

By
What does it take to implement an end-to-end-business model, meaning a single CDMO/CMO providing development and manufacturing services for both active pharmaceutical ingredients (APIs) and drug products? DCAT Value Chain…

Straight Talk: End-to-End CDMO/CMO Business Models
By

By
In an industry roundtable, DCAT Value Chain Insights examines the current and future state of the end-to-end business model for CDMOs/CMOs, in which one provider offers development and manufacturing services…